CONVERT PHARMACEUTICALS
Convert Pharmaceuticals is a preclinical stage drug development company, that is building a proprietary drug pipeline exploiting tumor microenvironment specific factors for therapeutic benefit.Convertโs lead product is a hypoxia activated prodrug (HAP). Hypoxia constitutes a therapeutic obstacle as it promotes the development of resistance to conventional anti-cancer treatments. Convert Pharmaceuticals combines proprietary insights in the tumor microenvironment with expertise in drug and biomarker development to develop effective and well-tolerated HAPs.
CONVERT PHARMACEUTICALS
Social Links:
Industry:
Biotechnology Business Development Pharmaceutical
Founded:
2017-01-01
Address:
Liรจge, Liege, Belgium
Country:
Belgium
Website Url:
http://www.convertpharma.com
Total Employee:
1+
Status:
Active
Contact:
+32 2 880 67 30
Email Addresses:
[email protected]
Total Funding:
13.6 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache
Similar Organizations
Ability Pharmaceuticals
Ability Pharmaceuticals is a drug discovery and development company.
Blade Therapeutics
Blade Therapeutics is a discovery stage drug development company.
Exo Therapeutics
Exo Therapeutics is a small molecule drug discovery and development company.
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Droia Ventures
Droia Ventures investment in Series A - Convert Pharmaceuticals
Meusinvest (Noshaq)
Meusinvest (Noshaq) investment in Series A - Convert Pharmaceuticals
Eurostars
Eurostars investment in Series A - Convert Pharmaceuticals
Spinventure
Spinventure investment in Series A - Convert Pharmaceuticals
Walloon
Walloon investment in Series A - Convert Pharmaceuticals
Official Site Inspections
http://www.convertpharma.com Semrush global rank: 5.23 M Semrush visits lastest month: 1.56 K
- Host name: 213.193.232.206
- IP address: 213.193.232.206
- Location: Berg en Terblijt Netherlands
- Latitude: 50.8609
- Longitude: 5.7887
- Timezone: Europe/Amsterdam
- Postal: 6325
More informations about "Convert Pharmaceuticals"
Convert Pharmaceuticals Home - Convert โฆ
Convert Pharmaceuticals is a pioneering platform company specializing in the development of prodrugs that remain inert until they reach the tumor site.See details»
About us - Convert Pharmaceuticals
Philippe Lambin is a Clinician, Radiation Oncologist, โERC advanced & twice ERC PoC grant laureateโ respectively from 2016, 2017 & 2020 and pioneer in โฆSee details»
Convert Pharmaceuticals - Crunchbase Company โฆ
Convert Pharmaceuticals is a research and development company. Convert Pharmaceuticals is a clinical phase I-IIa drug development company, that is โฆSee details»
Convert Pharmaceuticals - LinkedIn
Convert Pharmaceuticals is a clinical-stage biotech company, developing a proprietary pipeline of biomarker-enabled hypoxia-activated prodrugs to treat resistant solid tumors.See details»
Convert Pharmaceuticals Overview | SignalHire Company Profile
Organization Website: convertpharma.com : Social Links: Phone Number: 32-2-880-67-30: Convert Pharmaceuticals industries Pharma: Headquarters Location: Quai Banning 6, Liège, โฆSee details»
Contact - Convert Pharmaceuticals
Convert Pharmaceuticals. Esplanade Simone Veil 1 4000 Liège, Belgium. [email protected]. linkedinSee details»
Overview, News & Similar companies - ZoomInfo.com
Feb 27, 2018 Convert Pharmaceuticals contact info: Phone number: +32 28806730 Website: www.convertpharma.com What does Convert Pharmaceuticals do? Convert Pharmaceuticals, โฆSee details»
Convert Pharmaceuticals | VentureRadar
Website: http://convertpharma.com/ Convert Pharmaceuticals is a preclinical stage drug development company focused on creating a proprietary drug pipeline that ...See details»
Convert Pharmaceuticals - Craft
Convert Pharmaceuticals has 5 employees across 3 locations and $16.61 m in total funding,. See insights on Convert Pharmaceuticals including office locations, competitors, revenue, โฆSee details»
Convert Pharmaceuticals | BIO-Europe Spring - Informa Connect
BIO-Europe Spring is the premier springtime partnering conference bringing together a โwhoสผs whoโ from biotech, pharma and finance in the most innovative biopharma clusters in Europe โฆSee details»
Convert Pharmaceuticals SA:Company Profile & Technical โฆ
Convert Pharmaceuticals SA is a company that provides Tumor microenvironment, Prodrug, Proprietary drug and more. Convert Pharmaceuticals SA is headquartered in Belgium Liège.See details»
Convert Pharmaceuticals - Company Profile - Tracxn
Feb 19, 2025 Convert Pharmaceuticals - Developer of small molecule based oncology therapeutics. Raised a total funding of $16.7M over 3 rounds from 4 investors. Founded by โฆSee details»
Convert Pharmaceuticals - F6S
Similar companies Retex Pharmaceuticals We develop revolutionary medicines Reneo Pharmaceuticals Pharma Leads Drug discovery platform Hybrigenics Advanced platform โฆSee details»
Convert Pharmaceuticals - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Convert Pharmaceuticals. Use the PitchBook Platform to explore the full profile.See details»
Convert Pharmaceuticals - Products, Competitors, Financials, โฆ
External validation of a radiomic signature to predict p16 (HPV) status from standard CT images of anal cancer patients. May 3, 2023. Abstract The paper deals with the evaluation of the โฆSee details»
Convert Pharmaceuticals - VentureRadar
Website: http://convertpharma.com/ Develops a proprietary drug pipeline targeting tumor microenvironment factors, focusing on hypoxia-activated prodrugs for effective ...See details»
Convert Pharmaceuticals - Crustdata Company Profile, Funding โฆ
Convert Pharmaceuticals is a research and development company. Convert Pharmaceuticals is a preclinical stage drug development company, that is building a proprietary drug pipeline โฆSee details»
Convert Pharmaceuticals awarded a prestigious EIC Accelerator grant
Mar 28, 2024 Convert Pharmaceuticals, a leader in developing innovative therapies for treatment-resistant cancers, is pleased to announce its recent achievement of being awarded โฆSee details»
Simplification for success: Rewiring the biopharma operating model
Mar 21, 2025 Thirty-seven of them expect their organization to pursue a simplification effort over the next 12 months. Thirty-two respondents say they believe they need a significantly different โฆSee details»
Latest news on Convertโs TUMAGNOSTIC study
4 days ago Convert Pharmaceuticals has achieved a major milestone by securing the maximum โฌ2.5 million non-dilutive grant from the prestigious European Innovation Council (EIC) โฆSee details»